Abiopharma

🔍 Nicholas Breisacher (Executive)

Company: Gentherm Inc (THRM)

Report Date: 2026-03-23

Detailed Transactions and Holdings:

• Acquired 353 shares of Common Stock (Direct)
  Date: 2026-03-23 | Code: A | equity_swap_involved: false | shares_owned_after: 5,891.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 102 shares of Common Stock at $28.64 per share (Direct)
  Date: 2026-03-23 | Code: F | equity_swap_involved: false | shares_owned_after: 5,789.00 | transaction_form_type: 4

Footnotes:

• F1: On March 14, 2023, the Reporting Person was granted performance-based restricted stock units (PSUs) under the 2013 Equity Incentive Plan. A portion of such PSUs are earned at 0% - 200% of the target grant award based on the Issuer's three-year cumulative adjusted EBITDA measured in 2025 (Adjusted EBITDA PSUs), and a portion of such PSUs are earned at 0% - 200% of the target grant award based on the Issuer's return on invested capital measured in 2025 (ROIC PSUs). The PSUs vest on the later of the date the Compensation and Talent Committee determines that the PSUs are earned and the third anniversary of the grant date. On March 14, 2026, the vesting period lapsed, and on March 23, 2026, the Compensation and Talent Committee determined that the Adjusted EBITDA PSUs were earned at 69.15% of the target performance level, and the ROIC PSUs were earned at 63.44% of the target performance level, which reflects a total payout of 40.35% of the PSUs granted on March 14, 2023.